Buerger’s disease (BD) is a relatively rare thrombotic, occlusive and non-atherosclerotic clinical syndrome of unknown etiology. In recent years, numerous epidemiological studies confirmed the strong association between chronic anaerobic periodontal infection and development of cardiovascular diseases, including BD. Therefore, the aim of this study is to clarify association between periodontal pathogens and Buerger’s disease. Confirmation of presence and identification of periopathogens in patients with BD can be considered crucial in developing novel therapies for BD. Further, periodontal therapy will lead to eventual improvement of BD patients’ condition.
The impaction of maxillary canines is one of the biggest challenges in orthodontics practice. This case report describes successful surgical and orthodontic approach to the treatment of palatally impacted maxillary canine in a 14-year-old boy. Intraoral clinical examination revealed an absence of the upper right canine, an ectopic position of the upper left canine and crowding in the maxillary arch. The impaction of right maxillary canine and class II malocclusion were confirmed by lateral cephalogram, orthopantomogram and cone beam computed tomography. In the first phase, a transpalatal arch to the upper first molar teeth was applied, first premolars were extracted, and brackets were placed on all teeth and nickel-titanium arch wire was applied. The initial orthodontic phase was soon thereafter followed by the surgical exposure and orthodontic traction of the impacted canine using ligature wire attached from the button with chain to the open coil on the arch wire. The orthodontic treatment took two years with satisfactory aesthetic and functional results at the end. This clinical case has shown that adequate treatment of impacted maxillary canine can be achieved by using combined surgical technique and appropriate orthodontic approach.
Amlodipine is a third generation dihydropyridine calcium channel blocker that is frequently used in therapy of hypertension. Among many side effects, amlodipine has been found associated with gingival overgrowth (GO) which usually occurs within the first three months of starting therapy at a dose of 10 mg/day. However, there are very few reports on amlodipine-induced gingival overgrowth (AIGO) at a lower dose (5 mg/day) and only after short term administration. A 64-year-old male patient with hypertension, who received amlodipine (5 mg/day) for four years, sought medical attention at the Department of Periodontology and Oral Medicine, Institute of Dentistry, Banja Luka, Bosnia and Herzegovina. The patient complained of masticatory problems due to extensive maxillary GO along with pain, bleeding, and foul odor. The clinical and the histological evidences were consistent with AIGO. The first line treatment consisted of the amlodipine substitution (amlodipine was replaced with enalapril, 5 mg/day) and the scaling and root planning/SRP. At one-month follow-up, drug replacement and SRP resulted in some reduction of the inflammation and significant reduction of symptoms. Further, gingivectomy/gingivoplasty helped overcome the effect of these drugs. The possibility of AIGO should be considered for a lower dose, as well as a late presentation.
Even though available literature suggests that low-level laser therapy can be efficiently used in treatment of oral pemphigus vulgaris, either independently or as a part of combined therapy approach, these results should be interpreted with caution since there are no solid evidence-based proofs to provide the guidelines for the treatment of pemphigus vulgaris with low-level laser therapy. Therefore, further long-term randomized controlled clinical studies are necessary in order to give any solid recommendations on the use of low-level laser therapy in the treatment of pemphigus vulgaris.
Introduction. Dental caries and periodontal disease are the most frequent oral diseases and therefore determine oral health condition. The aim of this study was to assess the efficiency of the preventive programme for improving oral health in primary school children from first to fourth grade in Banjaluka. Material and methods.. Triennial study started in 2005 and included 911 second grade and 1491 fourth grade pupils in primary schools in Banjaluka. The study was completed in 2008. In the school year of 2007/08, 885 fourth grade pupils (examined in 2005. as second grade pupils) who were comprised by prevention program were reexamined. Dental check-ups were conducted by dentists on daylight using dental mirror and dental probe. Caries prevalence was analyzed using the DMFT index while oral hygiene was assessed using oral hygiene index (OHI). Results. The structure of DMFT among the second grade pupils (in the school year 2005/06) showed that the dominant component of DMFT was for healthy teeth (81%), followed by decayed (14%) and filled teeth (5%). The average value of OHI was 1.47 for this group of pupils. The structure of DMFT in the fourth grade pupils (in the year 2005/06) showed that the dominant component of DMFT was also for healthy teeth (75%). The next were decayed (18%) and filled teeth (7%). The average value of OHI was 1.60. Data analyses in the school year 2007/08 from the fourth grade pupils (who were second grade pupils during the school year 2005/06) and were comprised by preventive programme, showed that DMFT had the dominant component of healthy teeth (81%) followed by 10% of decayed teeth and 8% of filled teeth. Extracted teeth were only 1%. OHI was 0.95. Conclusion. The preventive programme applied in primary schools in Banjaluka since 2005. decreased the number of oral diseases and improved oral hygiene among the children who participated in this program
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.